There's nothing like a surge in a deadly disease to encourage investors back into a noted healthcare stock. This dynamic benefited biotech (NASDAQ: NVAX) on Thursday.

It was also on the back of one pundit's recommendation upgrade; together these factors sent the company's share price 8% skyward. That performance trounced that of the S 500 index, which essentially traded sideways.

The latest COVID subvariant, Eris, is beginning to get significant coverage in the media. For instance, on the website of the TV news magazine Today, Eris was described as "sweeping" through this country.

Continue reading

Source Fool.com